Patient
SITE011-0038
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE011 (ITA) (Dr. Jansen)
consented 2025-10-10
Adverse events
7
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 303); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-31 (study day 254); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 236); relationship: not assessed
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-17 (study day 57); relationship: NOT RELATED
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 36); relationship: NOT RELATED
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-05-21 (study day 30); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-05-16 (study day 25); relationship: NOT RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.